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ABSTRACT
Melanoma-associated antigen A1 (MAGEA1) and BORIS (also
known as CTCFL) are members of the cancer testis antigen (CTA)
family. Their functions and expression-regulation mechanisms are
not fully understood. In this study, we reveal new functions and
regulatory mechanisms of MAGEA1 and BORIS in breast cancer
cells, which we investigated in parental and genetically manipulated
breast cancer cells via gene overexpression or siRNA-mediated
downregulation. We identified the interaction between MAGEA1 and
CTCF, which is required for the binding of MAGEA1 to the BORIS
promoter and is critical for the recruitment of DNMT3a. A protein
complex containing MAGEA1, CTCF and DNMT3a was formed
before or after conjunction with the BORIS promoter. The binding of
this complex to the BORIS promoter accounts for the hypermethylation
and repression of BORIS expression, which results in cell death in the
breast cancer cell lines tested. Multiple approaches were employed,
including co-immunoprecipitation, glutathione S-transferase pull-down
assay, co-localization and cell death analyses using annexin V-FITC/
propidium iodide double-staining and caspase 3 activation assays,
chromatin immunoprecipitation and bisulfite sequencing PCR assays
for methylation. Our results have implications for the development of
strategies in CTA-based immune therapeutics.
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INTRODUCTION
Cancer testis antigens (CTAs) have been extensively studied in a
variety of cancers of diverse histological origin and germinal cells
(Lim et al., 2012; Zajac et al., 2017). However, the majority of these
studies focused on the correlative expression data and/or on
evaluating their immunotherapeutic targeting or tumor biomarker
values, with limited studies on their gene expression regulation and
even fewer on their cellular function in cancer cells (Lim et al.,
2012; Kulkarni and Uversky, 2017).
It is generally accepted that their expression is controlled by
epigenetics and by methylation in particular (Lim et al., 2012; Zajac
et al., 2017; Adair and Hogan, 2009; Schwarzenbach et al., 2014).
In addition, the gene regulation among different CTAs has been
reported in several cases, including the methylation-independent
transcriptional regulation of TSP50 (a CTA; also known as
PRSS50) by the brother of the regulator of imprinted sites
(BORIS; also known as CTCFL) (Zajac et al., 2017) and BORIS-
activated and methylation-dependent MAGEA1 expression
(Schwarzenbach et al., 2014; Vatolin et al., 2005; Loukinov et al.,
2006). However, expression of MAGEA1 occurs in the absence of
BORIS activation, suggesting that BORIS is not an obligate factor
for activation of MAGEA1 in melanoma (Kholmanskikh et al.,
2008). Contradictory and opposing effects (both tumor promoting
and suppressing) have been reported for these CTAs and their
related genes/proteins, including CTCF (Salmaninejad et al., 2016).
MAGEA1 promotes melanoma proliferation and migration through
C-JUN (also known as JUN) activation (Wang et al., 2016), but
MAGEA4 interacts with the liver oncoprotein gankyrin and
suppresses its tumorigenic activity (Nagao et al., 2003). We have
recently shown that MAGEA1 inhibits cell proliferation and
migration in breast and ovarian cancer cells via its interaction
with FBXW7 and regulates ubiquitin ligase-mediated turnover of
NICD1 (Zhao et al., 2017). Similarly, the role of BORIS in cancer is
not clearly defined. Although it has been hypothesized and
demonstrated to exhibit oncogenic properties (Horibe et al., 2017;
Tiffen et al., 2013; Zampieri et al., 2014), its inhibitory effects have
also been reported (Tiffen et al., 2013). CTCF, however, has been
postulated to be a candidate tumor suppressor (Tiffen et al., 2013).
BORIS is a complex and highly versatile transcription factor
(Kalejs and Erenpreisa, 2005; Klenova et al., 2002) and has been
shown to activate MAGEA expression via demethylation in various
cell types (Kang et al., 2007; Vatolin et al., 2005). Aberrant BORIS
expression has been detected in 70% of all primary tumors and
cancer cell lines (D’Arcy et al., 2008; Hong et al., 2005; Pugacheva
et al., 2010; Smith et al., 2009; Tiffen et al., 2013; Vatolin et al.,
2005). In addition, BORIS has been implicated in numerous
regulatory functions (Klenova et al., 2002; Monk et al., 2008;
Suzuki et al., 2010). BORIS has been shown to be mainly regulated
by promoter methylation modification (Hoffmann et al., 2006;
Loukinov et al., 2002; Woloszynska-Read et al., 2007), and
hypomethylation results in the universal expression of BORIS in
cancer cells (Renaud et al., 2007; Woloszynska-Read et al., 2007,
2011). The expression of BORIS is suppressed by CTCF binding to
its promoter and enhanced promoter methylation (Renaud et al.,
2007). CTCF is the only paralog of the BORIS gene, sharing a
central 11-zinc-finger DNA-binding domain, but having distinct
amino and carboxy termini (D’Arcy et al., 2008; Hore et al., 2008;
Klenova et al., 2002; Loukinov et al., 2002). In contrast to BORIS,
which has restricted expression in testis among normal tissues,
CTCF is ubiquitously expressed and often displays opposite
functions to those of BORIS (Barski et al., 2007; Heath et al.,
2008; Hore et al., 2008; Kim et al., 2007; Lobanenkov et al., 1990;
Loukinov et al., 2002).
These published data suggest that the regulation and functions of
these CTAs are rather complex and can be cancer type, cell line and/
or context dependent. As these CTAs are targets for tumor
immunotherapy, it is important to conduct more studies on the
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regulatory mechanisms of their aberrant expression and cellular
functions in cancers. Our current study focuses on the functions and
aberrant gene regulation of MAGEA1 and BORIS, two CTA family
members, in breast cancer cells. Functional and in-depth mechanistic
studies were performed using multiple approaches. These included
examination of the functions and cellular locations of the endogenous
and genetically manipulated genes involved via cell death analyses
using the annexin V-fluorescein isothiocyanate (FITC)/propidium
iodide (PI) double-staining method and caspase 3 activation,
co-immunoprecipitation (co-IP), glutathione S-transferase (GST)
pull-down, co-localization, chromatin immunoprecipitation (ChIP)
and methylation analyses.
RESULTS
MAGEA1 inhibits BORIS expression in various breast and
ovarian cancer cell lines
We have found that several breast cancer cell lines, such as MCF-7,
MDA-MB-231 and MDA-MB-468 express low or non-detectable
MAGEA1, and SKOV3 cells express a relatively high level of
MAGEA1 (Zhao et al., 2017; Fig. 1). As BORIS, another CTA
member, has been shown to be a positive regulator of MAGEA1
expression (Kang et al., 2007; Schwarzenbach et al., 2014; Vatolin
et al., 2005), we examined BORIS expression levels in breast cancer
cells (MCF-7 and MDA-MB-231), in comparison to non-cancerous
breast cells (MCF-10A). As expected, the expression of BORIS was
not detectable in non-cancerousMCF10A cells, because BORIS is a
CTA protein, but it was expressed at reactively high levels in breast
cancer cells (MCF-7 andMDA-MB-231) (Fig. S1A,B). Unexpectedly,
and in contrast to the positive relationship between BORIS and
MAGEA1 expression previously reported (Schwarzenbach et al., 2014;
Kang et al., 2007; Vatolin et al., 2005), the expression of the two genes
appeared to be negatively correlated in the cell lines tested (Fig. 1A). To
determine their functional relationship, we overexpressed or
downregulated [using small interfering RNA (siRNA)] MAGEA1 in
cells. MAGEA1 overexpression significantly inhibited BORIS
expression in MCF-7 and MDA-MB-231 cell lines (Fig. 1B), and
MAGEA1 downregulation (Fig. S2A) enhanced BORIS expression in
SKOV3 cells (Fig. 1C). Protein expression levels in control and
MAGEA1 genetically manipulated cells also showed that MAGEA1
expression had an inhibitory effect on BORIS expression (Fig. 1D).
These data revealed a previously unreported regulation of BORIS
expression by MAGEA1.
Fig. 1. The inhibitory effects of
MAGEA1 on expression of BORIS in
breast and ovarian cancer cells.
(A) BORIS mRNA expression levels in
MCF-7, MDA-MB-231 and SKOV3 cell
lines, analyzed by qPCR in A to C.
GAPDH was used as an internal
standard to normalize the expression
levels. Statistical analysis of –ΔΔCT
values relative to MCF-7 in each group
was performed. (B,C) Effects of
MAGEA1 overexpression (B) and
knockdown (C) on BORIS expression in
MCF-7, MDA-MB-231 and SKOV3 cells.
(D) The expression levels of BORIS
protein in the control and MAGEA1-
overexpressing cell lines as detected by
western blot analyses. All experiments
were repeated at least three times.
*P<0.05; **P<0.01; ***P<0.001.
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BORIS is involved in MAGEA1-induced cell death
To determine the functional consequences of BORIS andMAGEA1
expression, we focused on apoptotic cell death. Using flow
cytometry analyses, we found that MAGEA1 overexpression
induced a significant increase in apoptotic (revealed by the
percentage of the annexin V-positive cells on the right side of the
x-axis) and necrotic (detected by the percentage of the PI-positive
cells on the top side of the y-axis) cell death from 2.25–5.97% total
annexin V-positive cells in the control (parental and vector-
transfected) cell lines to∼21.14–22.09% annexin V-positive cells in
MAGEA1-overexpressing MCF-7 and MDA-MB-231 cell lines
(Fig. 2A–D). In addition, MAGEA1 overexpression in MCF-7 and
MDA-MB-231 cell lines activated caspase 3, revealed by the
detection of cleaved caspase 3 (Fig. 2E,F).
To determine the effect of BORIS expression on cell death, we
first downregulated BORIS inMCF-7 andMDA-MB-231 cell lines.
Reduced BORIS expression resulted in increased cell death, similar
to that induced byMAGEA1 overexpression (Figs S2B and S3A,B).
On the other hand, BORIS overexpression reduced cell death (both
apoptotic and necrotic) in MCF-7 and MDA-MB-231 cells
(Fig. 2C,D, upper rows). To test whether the MAGEA1-induced
cell death was mediated by BORIS, we overexpressed BORIS in
MAGEA1-overexpressing cells. BORIS partially reversed the cell
death induced by MAGEA1 (Fig. 2C,D, lower rows). The effects
were further demonstrated in the annexin V and PI double-positive
cell population (from∼26.0% to 15.6% inMCF-7 cells, or 21.7% to
11.21% in MDA-MB-231 cells) (Fig. 2C,D), suggesting that the
cell death mechanisms may be complex. When BORIS was
Fig. 2. BORIS reversed the inducing effects of MAGEA1 on apoptosis in breast cancer cells. (A,B) Annexin V-FITC/PI staining detected by flow cytometry
analyses in control MCF-7, MDA-MB-231 (pHM6 empty vector plasmid transfected) and their MAGEA1-overexpressing cells. (C,D) Apoptosis levels were
detected in MCF-7 (C), MDA-MB-231 (D) and their derived cells: wild-type cells, BORIS-overexpressing cells, MAGEA1-overexpressing cells, and MAGEA1 and
BORIS co-overexpressing cells. (E,F) Caspase 3 activation was detected in MCF-7 (E) and MDA-MB-231 (F) parental and MAGEA1-overexpressing cells by
western blotting. All experiments were repeated at least three times.
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downregulated, the annexin V-positive, PI-positive and double-
positive cell populations were increased (Fig. S3), supporting the
promoting effects of BORIS on cell survival.
CTCF was required for MAGEA1-induced suppression of
BORIS expression
Because CTCF is a known repressor of BORIS expression (Renaud
et al., 2007), we tested whether CTCF was involved in MAGEA1-
induced downregulation of BORIS. As expected, downregulation of
CTCF and upregulation of MAGEA1 increased and decreased
BORIS expression, respectively, in both MDA-MB-231 and MCF-
7 cells (Fig. 3A–C). When CTCF was downregulated in MAGEA1-
overexpressing cells, it completely reversed the inhibitory effect of
MAGEA1 on BORIS expression, suggesting that CTCF is
necessary for this effect (Fig. 3A–C). The requirement for CTCF
was not mediated by a potential regulatory role of MAGEA1 in
CTCF expression, as we found that CTCF expression was not
significantly changed at the mRNA and protein levels when
MAGEA1 expression was altered in MCF-7, MDA-MB-231 and
SKOV3 cells (Fig. S4A–D).
To elucidate the mechanisms of the CTCF requirement,
we tested whether MAGEA1 and CTCF interact with each other.
The interaction between these two proteins was first detected by
co-IP in MCF-7 cells using either an anti-hemagglutinin (HA)
(Fig. 3D) or anti-GFP antibody (Fig. 3E) to pull down the
HA-tagged MAGEA1 or GFP-fused CTCF proteins and their
interacting partner, which was detected byboth antibodies inwestern
blots. This interaction was confirmed using GST pull-down assays
(Fig. 3F). Importantly, we showed that endogenous MAGEA1 in
CTCF proteins interactedwith each other in SKOV3 cells, where both
proteins were expressed endogenously at significant levels (Fig. 3G).
Moreover, bothMAGEA1 andCTCFwere localized and co-localized
in nuclei, consistent with interaction and transcription factor activities
(Fig. 3H).
Compared with MAGEA1 overexpression, CTCF downregulation
had a relatively weak effect on cell death detected by PI- and annexin
V-positive cells (Fig. 4A,B). This effect was likely to be MAGEA1
independent, because MCF-7 and MDA-MB-231 cells did not
express detectable endogenous MAGEA1 (Zhao et al., 2017; Fig. 1).
However, CTCF downregulation strongly reduced cell death induced
by overexpression ofMAGEA1 in these cells (Fig. 4A,B), suggesting
that CTCF is the critical factor mediating the effects of MAGEA1 on
cell death.
CTCF is required for the enhanced methylation induced by
MAGEA1 on the BORIS promoter
We conducted ChIP analyses and showed that both MAGEA1 and
CTCF bound to the promoter of BORIS (Fig. 5A,B; Fig. S5A–C).
The binding of MAGEA1 to the promoter of BORIS was
significantly affected by downregulation of CTCF using siRNA-
mediated RNA interference (Fig. 5C,D; Fig. S5D,E), suggesting
that CTCF is important for the binding ability of MAGEA1 to the
BORIS promoter.
MAGEA1 overexpression greatly increased methylation of the
BORIS promoter, as detected by bisulfite sequencing, in MCF-7
and MDA-MB-231 cells (Fig. 6A–D). This enhancement activity
was significantly reduced when CTCF was downregulated by
siRNA interference in MCF-7 cells (Fig. 6E). In addition, the
endogenous methylation level of the BORIS promoter was high in
SKOV3 cells, where MAGEA1 was relatively highly expressed
(Fig. 6F), although the endogenous CTCF expression levels in
MCF-7, MDA-MB-231 and SKOV3 cells were comparable
(Fig. S4D). These data suggest that MAGEA1 is the driving force
for the methylation of the BORIS promoter, which requires CTCF.
However, CTCF expression in the absence of MAGEA1 in MCF-7
and MDA-MB-231 cells (Fig. S4D) is insufficient to induce
extensive methylation in the BORIS promoter.
DNMT3a participates in the formation of theMAGEA1–CTCF–
DNMT3a complex
DNMT3a, an enzyme that catalyzes the transfer of methyl groups
to specific CpG structures in DNA, was found to interact with both
MAGEA1 and CTCF by GST pull-down assay in MCF-7 cells
(Fig. 7A). When CTCF was downregulated, the interaction
between MAGEA1 and DNMT3a was significantly decreased
(Fig. 7B), suggesting that CTCF is important for the tri-interaction.
Immunofluorescence experiments further confirmed that these
proteins, MAGEA1 or CTCF and DNMT3a, were co-localized in
nuclei in MCF-7 cells (Fig. 7C). On the other hand, MAGEA1
overexpression did not affect the interaction between CTCF and
DNMT3a (Fig. 7D).
We tested the role of another DNA methyltransferase, DNMT1.
WhenDNMT1 expressionwas downregulated by siRNA interference
in breast cancer cells, MAGEA1 expression was increased, similar to
that reported in melanoma cells (Cannuyer et al., 2013). Under these
conditions, BORIS expressionwas repressed (Fig. S6A,B), consistent
with ourMAGEA1 overexpression data shown in Fig. 1B. Moreover,
MAGEA1overexpression andDNMT1knockdownboth induced cell
apoptosis (Fig. S6C). However, unlike DNMT3a, DNMT1 was not
shown to interact with MAGEA1 and CTCF in MCF-7 cells by GST
pull-down assays (Fig. 7E), suggesting that the MAGEA1–DNMT3a
interaction is specific.
CTCF recruits DNMT3a to the promoter of BORIS, while
MAGEA1 enhances the promoter methylation of BORIS by
DNMT3a
To investigate whether DNMT3a was functionally involved in the
inhibition of BORIS expression by MAGEA1, we performed ChIP
assays in MCF-7 cell lines. Downregulation of CTCF resulted in
reduced binding of DNMT3a to the promoter of BORIS,
independent of MAGEA1 expression (Fig. 8A). Bisulfite
sequencing PCR assays revealed that downregulation of DNMT3a
resulted in reduced methylation of the BORIS promoter, even when
MAGEA1 was overexpressed (Fig. 8B–D). In addition, we tested
the functional consequences of downregulation of DNMT3a in cell
death induced by MAGEA1 overexpression in MCF-7 and MDA-
MB-231 cell lines. As shown in Fig. 8E and F, reduced DNMT3a
expression reversed a significant portion of the MAGEA1-induced
cell death.
On the other hand, knockdown of DNMT1 did not significantly
affect the methylation of the BORIS promoter in the absence
and presence of MAGEA1 overexpression (Fig. S7A–C; compare
Fig. S7C with Fig. 8B), suggesting that DNMT1 is not functionally
involved in this activity.
Our collective data presented in this study demonstrate that the
negative regulatory effect ofMAGEA1 on cell survival wasmediated
by its repressive regulatory effect on BORIS expression in the breast
cancer cell lines tested. CTCF was required for MAGEA1 to bind to
the promoter of BORIS and for the recruitment of DNMT3a for
enhanced methylation in the promoter region. DNMT3a, but not
DNMT1, was likely the major methyltransferase responsible for
DNA methylation and repression of BORIS expression. CTCF and
DNMT3a were also functionally involved in MAGEA1-induced cell
death.
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Fig. 3. CTCF is functionally involved in the inhibition of BORIS by MAGEA1. (A,B) MAGEA1 cannot inhibit BORIS expression under the condition of CTCF
knockdown in MCF-7 and MDA-MB-231 cells analyzed by qPCR. (C) Western blot assay confirmed that MAGEA1 cannot inhibit BORIS expression without
CTCF. (D,E) The interaction between MAGEA1 and CTCF was identified in MCF-7 cells. The expression levels of the proteins encoded by the input
genes (transfected GFP-tagged CTCF, HA-tagged MAGEA1) were confirmed by western blot analyses. The incubated proteins are indicated. The antibodies
used in the immunoprecipitation (IP) or western blot steps are labeled on each row. (F) GST pull-down assay confirmed the interaction between MAGEA1 and
CTCF in MCF-7 cells. All of the incubated proteins and antibodies used in the IP and western blot steps are indicated. (G) Co-IP assays were conducted using
anti-CTCF antibodies for endogenous proteins in SKOV3 cells. The antibodies used in the IP step are indicated at the top, with the protein G magnetic bead
linked to rabbit IgG as the control. The antibodies used in the western blot step are labeled on the right. (H) The subcellular localizations of MAGEA1 and CTCF
were identified by immunofluorescence co-localization assays in MCF-7 cells. MAGEA1 fused to GFP showed green fluorescence, and CTCF was detected by
TRITC red fluorescence. Nuclei were stained by DAPI (blue fluorescence). Scale bars: 50 μm. All experiments were repeated at least three times. *P<0.05;
**P<0.01.
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DISCUSSION
To make CTAs effective and practical targets for tumor
immunotherapy, it is important to conduct more studies on the
regulatory mechanisms of their aberrant expression and cellular
functions in cancers. The published data, as reviewed in the
Introduction, suggest that the regulation and functions of these CTAs
Fig. 4. Downregulation of CTCF reversed cell death induced by MAGEA1. (A,B) Annexin V-FITC/PI staining-based flow cytometry analyses detected the cell
death (both apoptotic and necrotic) in MCF-7, MDA-MB-231 and their derived cell lines, including MAGEA1-overexpressing cells, CTCF siRNA interference cells,
and MAGEA1-overexpressing and CTCF siRNA interference cells. All experiments were repeated at least three times.
Fig. 5. Downregulation of CTCF reduced
MAGEA1 binding to the promoter of
BORIS. (A,B) ChIP analysis of MAGEA1
and CTCF binding to the BORIS promoter in
MCF-7 (A) and MDA-MB-231 (B) cell lines.
(C,D) The effect of CTCF downregulation of
MAGEA1 binding to the BORIS promoter
analyzed by ChIP in MCF-7 (C) and MDA-
MB-231 (D) cells. All experiments were
repeated at least three times. *P<0.05;
**P<0.01; ***P<0.001.
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are rather complex and can be cancer type, cell line and/or context
dependent (Lim et al., 2012; Zajac et al., 2017). In this study, we
have shown that MAGEA1 induces cell death in the breast cancer
cell lines tested and revealed the mechanisms involved in depth.
Although it has been shown that BORIS activates MAGEA
expression via demethylation in various cell types (Kang et al.,
2007; Vatolin et al., 2005), we demonstrate here, for the first time,
that MAGEA1 has a negative regulatory effect on BORIS
expression, and that downregulation of BORIS is functionally
involved in MAGEA1-induced cell death in breast cancer cells.
These findings emphasize that different CTAs may play opposing
roles in the same or different cells and may counter-regulate each
other.
Although CTCF has been reported to inhibit BORIS expression,
the molecular mechanisms are not fully understood (Renaud et al.,
2007). While we have shown a consistent negative regulatory role of
CTCF in BORIS expression in breast cancer cells, new mechanisms
have been revealed. We have identified an interaction between
MAGEA1 and CTCF, which binds to the BORIS promoter and
represses its expression. In addition, we found that CTCF plays
crucial roles in MAGEA1-binding capacity to the BORIS promoter
and recruitment of DNMT3a to the same complex. Consequentially,
downregulation of CTCF reversed the effects of MAGEA1 on
BORIS expression and cell death, as well as the interaction between
MAGEA1 and DNMT3a. Interestingly, although CTCF is
important for the effect of MAGEA1 on BORIS, relatively high
levels of CTCF expression in the absence of MAGEA1 expression
(such as the endogenous levels in MCF7 and MDA-MB-231 cells;
Fig. 3C) are insufficient for induction of hypermethylation of the
BORIS promoter (Fig. 6), implying that MAGEA1 is essential to
regulate DNMT3a-mediated methylation of the BORIS promoter.
On the other hand, although we have found that DNMT1
downregulation is accompanied by MAGEA1 upregulation and
repression of BORIS expression, DNMT1 was not required for
Fig. 6. MAGEA1-induced methylation in the BORIS promoter requires CTCF. (A–D) Genomic bisulfite sequencing of CpGs within the CpG island in MCF-7
(A), MDA-MB-231(C) and their MAGEA1-overexpressing cell lines (B,D). (E) Downregulation of CTCF reduced MAGEA1-induced methlyation in MCF-7 cells.
MCF-7+MAGEA1+CTCF-Ri indicates MAGEA1 overexpression but that BORIS was knocked down by siRNA-mediated RNA interference. (F) Endogenous
methylation in the BORIS promoter in SKOV3 cells. Open circles (○) and filled circles (●) represent non-methylated CpGs andmethylated CpGs, respectively. All
experiments were repeated at least three times.
7
RESEARCH ARTICLE Journal of Cell Science (2019) 132, jcs218628. doi:10.1242/jcs.218628
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
MAGEA1-induced methylation of the BORIS promoter. These
results suggest that a different mechanism is involved in BORIS
regulation by DNMT1, which warrants further investigation.
We have identified that DNMT3a, but not another
methyltransferase, DNMT1, is responsible for the MAGEA1-
induced increased methylation of the BORIS promoter. In addition,
Fig. 7. DNMT3a interacted with MAGEA1 and CTCF. (A) GST pull-down assays performed between DNMT3a and MAGEA1 or CTCF. All of the incubated
proteins and antibodies used in the IP and western blot steps are indicated. (B) When CTCF was downregulated (lane 3), DNMT3a co-immunoprecipitation was
significantly reduced compared with that in the control (lane 2) MCF-7 cells. (C) The subcellular localizations of MAGEA1 or CTCF and DNMT3a in MCF-7 cells
were identified by immunofluorescence. MAGEA1 or CTCF was fused to GFP, showing green fluorescence. DNMT3a was detected by TRITC red fluorescence
and nuclei were stained with DAPI (blue fluorescence). (D) Co-localization between CTCF and DNMT3a was detected in MCF-7 control and MAGEA1-
overexpressing cells. (E) GST pull-down assay between MAGEA1 or CTCF and DNMT1. Scale bars: 50 μm. All experiments were repeated at least three times.
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DNMT3a physically interacts with CTCF and is functionally
involved in MAGEA1-induced cell death.
Our results presented here are consistent with reports of BORIS
oncogenic activities. As a transcription factor, BORIS activatesmany
oncogenes, includingTSP50,TERT,OCT4 (also known asPOU5F1)
and c-Myc (also known asMYC) (Bhan et al., 2011; Liu et al., 2017;
Smith et al., 2009; Vatolin et al., 2005; Yang et al., 2015). Selective
apoptosis of breast and colorectal cancer cells was observed by
Fig. 8. DNMT3a is functionally involved with MAGEA1. (A) ChIP analysis of DNMT3a binding to the BORIS promoter in MCF-7 cells with MAGEA1
overexpression or CTCF knockdown. (B–D) Methylation levels detected in MAGEA1-overexpressing (B), DNMT3 knockdown (C), and MAGEA1-overexpressing
and DNMT3a knockdown (D) MCF-7 cells. (E,F) Annexin V-FITC/PI staining-based flow cytometry detected the apoptosis in MCF-7 (E), MDA-MB-231 (F)
parental and their derived cell lines: MAGEA1-overexpressing cells, DNMT3a knockdown cells, andMAGEA1-overexpressing and DNMT3a knockdown cells. All
experiments were repeated at least three times. **P<0.01; ***P<0.001.
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inhibiting BORIS expression (Dougherty et al., 2008; Zhang et al.,
2017). Our annexin V-FITC/PI double-staining assays also show that
BORIS has a protective role in MAGEA1-induced cell death.
In conclusion, the current study demonstrates a newly detected
tri-complex among MAGEA1, CTCF and DNMT3a. The binding
of this complex to the BORIS promoter accounts for the
hypermethylation and repression of BORIS expression, which
results in subsequent cell death in the breast cancer cell lines tested.
Each of the three proteins play interactive, yet distinct, roles in
BORIS expression and subsequent cell death. While CTCF is
critical for the ability of MAGEA1 to bind to the BORIS promoter,
and for the recruitment of DNMT3a, CTCF itself is insufficient to
induce hypermethylation in the absence of MAGEA1. On the other
hand, MAGEA1 is essential for the induction of hypermethylation
of the BORIS promoter, potentially via a direct interaction with
DNMT3a to recruit and/or activate DNMT3a, which remains to be
further investigated.DNMT3a is likely the enzymedirectly catalyzing
the methylation, but it relies on both MAGEA1 and CTCF to
effectively exert its activity on the BORIS promoter. The mechanistic
connections of these proteins are supported by our functional studies
conducted. These new findings are likely to have implications in
developmental strategies for CTA-based immunotherapeutics.
MATERIALS AND METHODS
Cell lines
Human breast cancer cell lines MCF-7 and MDA-MB-231 were obtained
from the American Type Culture Collection. The ovarian cancer cell line
SKOV3 was a generous gift from Prof. Cui (Peking University RenMin
Hospital, Beijing, China). All cells were cultured in Dulbecco’s modified
eaglemedium (DMEM)with 10% fetal calf serum.Cellsweremaintained in a
humidified incubator at 5% CO2 and 37°C. The cell lines MCF-7 andMDA-
MB-231 have been authenticated and tested for contamination recently.
Plasmids, siRNA and transfection conditions
The entire coding regions of MAGEA1 and BORIS were obtained from
complementary DNA prepared from SKOV3 andMCF-7 cells, respectively,
by RT-PCR. The primers used for these cloning steps are listed in Table S1.
MAGEA1was subcloned into the pEGFP-C1 or pHM6-HA plasmid vectors
using the EcoRI/KpnI and HindIII/EcoRI sites, respectively. BORIS was
subcloned into pCMV-14-flag using the EcoRI/KpnI sites. The CTCF
coding region was purchased from the Shanghai Genechem Company
(Shanghai, China) and subcloned into pcDNA-3.1-GFP plasmid vectors
using the EcoRI/XbaI sites. For cell-free expression systems,MAGEA1 and
CTCF were subcloned into pcDNA-3.1-GST using the EcoRI/XbaI sites.
The overexpression plasmid vectors were transfected into MCF-7 and
SKOV3 cells with Vigofect (Vigorous Biotechnology, Beijing, China), and
into MDA-MB-231 cells with Ploylus jetPRIME (Polyplus, Illkirch-
Graffenstaden, France), according to the manufacturer’s instructions. The
gene expression levels were detected by RT-PCR 24 h after transfection, and
protein was detected at 36 h with western blot analyses.
For siRNA transfection, subconfluent MCF-7, SKOV3, or MDA-MB-231
cells were transiently transfected using Ploylus jetPRIME with 40 nM non-
silencing control siRNA (GenePharma, Shanghai, China) or 100 nM gene-
specific targeting siRNAs (GenePharma). The sequences of these siRNAs are
listed in Table S2. DNMT3a siRNA sequences were the same as those
previously reported (Xu et al., 2014). The transfection procedure (including
dosage) was performed according to the manufacturer’s instructions.
Quantitative real-time PCR
Quantitative real-time PCR (qPCR) was conducted using a QuantStudio
Flex real-time PCR system (Thermo Fisher Scientific, Waltham, MA, USA)
and TransStart Top Green qPCR SuperMix (Transgene Biotech, Beijing,
China). The sequences of the primers used are listed in Table S3. The
detailed steps and RNA extraction methods were performed as described
previously (Zhao et al., 2017).
Western blot analyses
Western blot analyses were performed as described (Zhao et al., 2017).
Proteins were detected with antibodies: anti-HA (Abcam, Cambridge,
UK), anti-GFP (Roche, Basel, Switzerland), anti-MAGEA1/BORIS and
anti-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CTCF
(Cell Signaling Technology, Boston, MA), anti-DNMT3a (Abcam), anti-
FLAG (Transgene Biotech), goat anti-mouse IgG and goat anti-rabbit IgG
(Cwbio, Beijing, China). The batch numbers and dilutions are listed in
Table S4.
Co-IP and GST pull-down assays
Cells were lysed in RIPA lysis buffer without sodium dodecyl sulfate
(SDS). Cell lysates (1 mg/sample) were incubated with specific
antibodies (4 µg) overnight at 4°C. The washed immunoprecipitates were
re-suspended in 30 μl of 2× SDS and the proteins were detected by western
blot analyses.
For GST pull-down assays in cell-free system, the proteins (GST-
MAGEA1, GST-CTCF) were synthesized using the TNT® Quick Coupled
Transcription/Translation System (Promega, Madison, WI, USA). The
protein (1 mg/sample) in PBS [pH 7.2–7.4 in the presence of with 1%
bovine serum albumin (BSA)] was added up to 600 μl (with 1% BSA).
Then, the mixed protein solution (to 600 µl) was incubated with specific
antibodies overnight at 4°C. After washing with PBS, the bound proteins
were detected using western blot analyses.
Flow cytometry analysis for assessment of cell death
Cell death rates were measured by flow cytometry using an annexin V-FITC/
PI apoptosis detection kit (Vazyme Biotechnology, Nanjing, China). MCF-
7 and MDA-MB-231 cells were collected at a concentration of
1×105 cells ml−1, mixed with annexin V-FITC and PI, according to the
manufacturer’s recommendation, and analyzed using a flow cytometer. Data
were analyzed using NovoExpress Software (ACEABioscience, San Diego,
CA, USA).
Immunofluorescent localization
Cells were cultured on glass coverslips for 24 h in DMEM containing 10%
fetal bovine serum. MAGEA1 was tagged by GFP, CTCF was tagged by
GFP or tetramethylrhodamine isothiocyanate (TRITC), and DNMT3a was
tagged by TRITC. Then, the cells were fixed for 20 min with 3.4%
formaldehyde and subsequently treated with 0.5% PBS-Triton X-100 for
10 min. After blocking with 3%BSA in PBS for 30 min, the coverslips were
covered with mouse primary antibodies against the tag and incubated at 37°
C for 1 h. This was followed by a 1 h incubation with goat anti-mouse IgG
tagged with TRITC (ZSGB-BIO Company, Beijing, China). For nuclear
staining, 4′,6-diamidino-2-phenylindole (DAPI) was used. The subcellular
localization of MAGEA1, CTCF or DNMT3a was detected by fluorescence
microscopy.
ChIP assays
MCF-7 and MDA-MB-231 cell lines were used in ChIP assays to examine
the cell binding of CTCF, MAGEA1 and DNMT3a to the BORIS promoter.
We used a ChIP assay kit (Beyotime Biotechnology, Shanghai, China) and
followed the manufacturer’s recommendations. One ChIP reaction used
10 µl anti-CTCF or 15 µl anti-DNMT3a/HA-MAGEA1 monoclonal
antibody. Immunopurified DNA was used in real-time PCR using the
primers listed in Table S5.
Bisulfite genomic sequence
DNAwas extracted from culture cells using an EasyPure Genomic DNAKit
(Transgene Biotech). The DNA was modified by sodium bisulfite using a
BisulFlash DNA Modification Kit (Epigentek, New York, NY, USA). The
experimental operation was carried out in accordance with the instructions.
After bisulfite modification, PCR on the BORIS promoter was performed
with the primers shown in Table S5. The PCR products were analyzed on
1% agarose gels (Magen Company, Guangzhou, China). The target bands
were extracted from the gel. The purified PCR products were cloned into
pMD19-T Vector (Takara, Tokyo, Japan). White-blue plaque selection was
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performed for positive bacterial strain selection. The products were then
sequenced and analyzed by BIQ_Analyzer Microsoft App (Max Planck
Institute for Informatics, Saarbrücken, Germany).
Statistical analyses
All experiments were conducted independently at least three times.
Statistical analyses were performed using Prism 5 (GraphPad, San Diego,
CA, USA) and the data are presented as mean±s.d. P-values were calculated
by two-sided Student’s t-test and P<0.05 was considered significant. Data
were obtained from three independent experiments and presented as average
values±s.e.m. (*P<0.05; **P<0.01; ***P<0.001).
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